Registration for a live webinar on 'Gamma-delta T cells for immunotherapy of cancer' is now open.See webinar details
Genetics and management of inherited cancer predisposition 1
Published on February 29, 2016 25 min
A selection of talks on Oncology
Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
- The Norwegian Radium Hospital, Norway
Drug metabolizing enzymes in cancer therapeutics
- Prof. Bhagwat Prasad
- University of Washington, USA
Key considerations for cancer pharmacotherapy 1
- Prof. Christine M. Walko
- H. Lee Moffitt Cancer Center, Tampa, USA
JOSHUA SHIFFMAN: Hello. My name is Joshua Shiffman. I am a pediatric oncologist at the University of Utah, where I take care of patients with hereditary cancer syndromes as well as do research in the field.
Today, we're going to talk about the importance of family history. We will cover several of the more common hereditary cancer syndromes including, GI cancers, breast cancers, Li-Fraumeni Syndrome, Paraganglioma and VHL syndromes. And finally, we'll end with some brief discussion about research in the field of hereditary cancers specifically related to comparative oncology.
Cancer is quite common. In fact, it is one of the leading causes of death around the world, and 15 people will die from cancer every minute. Half of all men and a third of all women will develop cancer throughout their lifetime. This makes the study of cancer and the risk for cancer quite relative to disease and impact on human health.
In terms of the genetic risk for cancer, we believe that as many as 1 in 10 adults will have cancer that is caused to an inherited genetic risk. This comes to approximately 160,000 new diagnoses per year for cancer in the US alone. In terms of childhood cancer, we believe that it may be as high as 1 in 3 children who have developed cancer due to an inherited genetic risk. This comes to approximately 4,500 new diagnoses for cancer per year.